|
Liver carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the DNA hypomethylation of the PCNA gene found in hepatocellular carcinoma was not due to cell proliferation, but a possible consequence of cell transformation.
|
8102592 |
1993 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
A concomitant decline in immunohistochemically detected number of the proliferating cell nuclear antigen (PCNA), a cell proliferation marker, in the HCC liver, further confirmed anti-cell proliferative role of Fisetin during HCC growth <i>in vivo</i>.
|
29298655 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We established that HCC transition from a moderate to poor stage involved densely connected clusters that comprised of PCNA, XRCC5, XRCC6, PARP1, PRKDC, and WRN.
|
21410269 |
2011 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Functionally, PCNAP1 or PCNA remarkably enhanced HBV replication and accelerated the growth of HCC <i>in vitro</i> and <i>in vivo</i>.
|
31410212 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma.
|
24704293 |
2014 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
To determine the relationship between ERRP expression and cell proliferation, we performed double staining for ERRP and proliferating cell nuclear antigen (PCNA) in the same HCC specimens.
|
15205570 |
2004 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our study investigated the effects of YSL on human hepatocellular carcinoma and cyclin, and explored its antitumor mechanism in vitro.
|
19491661 |
2009 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
P53 Ser15-P is associated with poor outcomes in patients with HCC, and this prognostic marker is useful for predicting the survival of patients with PCNA-positive HCC.
|
30881947 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In contrast, there was no correlation between c-myc overexpression, found in 19 out of 40 HCC (47.5%), and histological grading of HCC or PCNA labeling index.
|
8104947 |
1993 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In double-labelling experiments, PCNA and HDV RNA staining did not co-localize, with the exception of two of three cirrhotic tissues associated with HCC, where the association between the two markers was statistically significant.
|
9097264 |
1997 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Further evidence at the molecular level indicated that celecoxib down-regulated the expression of phospho-ERK (Thr202/Tyr204) and proliferating cell nuclear antigen (PCNA) in the HCC mice.
|
30182439 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found that TFP in vivo could effectively restrict the angiogenesis and tumor growth with reduced expression of VEGF, Bcl-2, and PCNA, and increased the nuclear localization of FOXO1, which indicated its antitumor role in HCC.
|
28876084 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
LHGDN |
PTEN down-regulation or p53 (+) correlated with increased HCC dedifferentiation, advanced pathologic stages and high PCNA labeling index (LI) of tumors (P<0.05).
|
17982625 |
2007 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Resected hepatoma tissue was stained immunohistochemically with antibodies for proliferating cell nuclear antigen (also called cyclin), a marker of cell proliferation.
|
7927250 |
1994 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
LHGDN |
The aim of the study was to analyze to what extent the presence of DNA-bound PCNA and p21 correlates with cell proliferation and DNA-repair in hepatocellular carcinoma (HCC).
|
14642618 |
2003 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study analyzed the correlation of aPKC-iota with clinicopathology in hepatocarcinoma and Cyclin E and investigated molecular mechanisms of invasion and metastasis of hepatocellular carcinoma.
|
19101699 |
2009 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The positive rate of PCNA in HCC was significantly higher compared to control (P<0.0001) and non-tumor liver tissues (P<0.0001).
|
23292006 |
2013 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings suggested that a miR-199/XBP1/cyclin D axis may serve an important role in the pathogenesis of HCC.
|
30405792 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Among the various types of cell-cycle regulators, p16 and p27 are frequently inactivated in HCC and are considered to be potent tumor suppressors. p16, a G1-specific cell-cycle inhibitor that prevents the association of cyclindependent kinase (CDK) 4 and CDK6 with cyclin D1, is frequently inactivated in HCC via CpG methylation of its promoter region. p16 may be involved in the early steps of hepatocarcinogenesis, since p16 gene methylation has been detected in subsets of pre-neoplastic liver cirrhosis patients. p27, a negative regulator of the G1-S phase transition through inhibition of the kinase activities of Cdk2/cyclin A and Cdk2/cyclin E complexes, is now considered to be an adverse prognostic factor in HCC.
|
18350604 |
2008 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The expressions of liver X receptor (LXR)-α, glucose transporter (Glut)-1, proliferating cell nuclear antigen (PCNA), and matrix metalloproteinase (MMP)-9 were analyzed from HCC public database (NCBI PubMed database).
|
30817182 |
2019 |
|
Liver carcinoma
|
0.300 |
Therapeutic
|
disease |
RGD |
PCNA index decreased from 80 in HCC rats to 32 after boron treatment.In the control group, it was 20.
|
23219601 |
2013 |
|
Liver carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
Interestingly, TFF1-positive cancer cells showed a staining pattern contradictory to that of proliferating cell nuclear antigen (PCNA), and aberrant DNA hypermethylation in TFF1 promoter lesions was detected in HCC samples, indicating the tumor-suppressive role of TFF1.
|
31733149 |
2019 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The analysis of the effects of NC on apoptosis in HCC tumor xenografts in mice was carried out by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay; the expression of Bcl-2, Bax, cyclin-dependent kinase (CDK)4, cyclin D1, p21 and proliferating cell nuclear antigen (PCNA) was analyzed by immunohistochemistry; and the protein expression of JAK1 and STAT3 was examined by western blot analysis.
|
23613111 |
2013 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Moreover, enhanced expression of NPM in HCC correlated with the level of PCNA (R(2)=0.5639) and with the clinical prognostic parameters such as serum alpha fetal protein level, tumour pathological grading, and liver cirrhosis (P<0.05).
|
17245342 |
2007 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
PCNA messenger RNA (mRNA) levels progressively increased from normals to CAH and to cirrhotic patients, and persisted at a high level in the tumorous and in the nontumorous area of HCC subjects, thus showing that the increase of IGF-II transcripts in CAH and cirrhosis is accompanied by an activation of cell mitosis in these samples.
|
8675143 |
1996 |